
Incyte INCY.O jumps 4% to $67.84 on Tues after the biopharma firm announced it will present new research data to support a potential treatment for blood cancer
INCY on track for biggest daily pct gain since Oct. 2024 and highest close in nearly three months
INCY said new research data from its "hematology/oncology" portfolio will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 – 15 in Milan
Among 27 analysts that cover INCY, avg rating is "BUY" and median PT is $73
INCY remains down ~2% YTD vs ~4 drop in the S&P 500 health index .SPXHC